Comparative Pharmacology
Head-to-head clinical analysis: CAM AP ES versus CAM METRAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAM AP ES versus CAM METRAZINE.
CAM-AP-ES vs CAM-METRAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAM-AP-ES is a combination antihypertensive containing camphor, apocynum, and eserine. The mechanism involves camphor as a mild vasodilator, apocynum as a cardiac glycoside with positive inotropic and negative chronotropic effects, and eserine as a cholinesterase inhibitor that enhances parasympathetic activity, leading to reduced heart rate and vasodilation.
CAM-METRAZINE (metformin and rosiglitazone combination) improves glycemic control by decreasing hepatic glucose production (metformin, AMPK activation) and increasing insulin sensitivity in peripheral tissues (rosiglitazone, PPARγ agonist).
CAM-AP-ES: Oral, 1-2 tablets twice daily. Each tablet contains camphor 30 mg, apomorphine 5 mg, and eserine 2 mg.
Initial dose: 30 mg orally once daily; may increase to 60 mg orally once daily after 2 weeks, then to 90 mg orally once daily after another 2 weeks. Maximum dose: 90 mg/day.
None Documented
None Documented
Terminal elimination half-life 10–12 hours in normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Terminal elimination half-life is 6-8 hours in adults with normal renal function; prolonged to 12-20 hours in moderate renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Renal: ~90% unchanged drug; biliary/fecal: ~10% as metabolites
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (5-10%).
Category C
Category C
Topical Analgesic
Topical Analgesic